Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MTNB Matinas BioPharma Holdings Inc
- Stocks
- Healthcare
- NYSEAMERICAN: MTNB
Price (delayed)
$0.873
Market cap
$4.44M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.86
Enterprise value
$230,938
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care for patients in areas of significant unmet medical need. Company leadership has
Highlights
The EPS has grown by 29% YoY and by 22% from the previous quarter
Matinas BioPharma Holdings's debt has decreased by 20% YoY and by 6% QoQ
The company's quick ratio fell by 24% YoY but it rose by 12% QoQ
The company's equity has shrunk by 57% YoY and by 17% QoQ
Key stats
What are the main financial stats of MTNB
Market
Valuations
Earnings
Shares outstanding
5.09M
Market cap
$4.44M
Enterprise value
$230,938
Price to earnings (P/E)
N/A
Price to book (P/B)
0.71
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$20.64M
Net income
-$20.08M
EBIT
-$20.16M
EBITDA
-$19.3M
Free cash flow
-$12.12M
Per share
Balance sheet
Liquidity
EPS
-$3.86
EPS diluted
-$3.86
Free cash flow per share
-$2.38
Book value per share
$1.23
Revenue per share
$0
TBVPS
$2.37
Total assets
$12.04M
Total liabilities
$5.77M
Debt
$2.71M
Equity
$6.27M
Working capital
$5.29M
Debt to equity
0.43
Current ratio
3.35
Quick ratio
3.09
Net debt/EBITDA
0.22
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-115.4%
Return on equity
-164.8%
Return on invested capital
-198.1%
Return on capital employed
-206.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MTNB stock price
How has the Matinas BioPharma Holdings stock price performed over time
Intraday
13.38%
1 week
23.83%
1 month
54.51%
1 year
-89.91%
YTD
71.18%
QTD
67.88%
Financial performance
How have Matinas BioPharma Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20.64M
Net income
-$20.08M
Gross margin
N/A
Net margin
N/A
The company's net income rose by 17% QoQ and by 14% YoY
The operating income has grown by 16% from the previous quarter and by 14% YoY
Price vs fundamentals
How does MTNB's price correlate with its fundamentals
Growth
What is Matinas BioPharma Holdings's growth rate over time
Valuation
What is Matinas BioPharma Holdings stock price valuation
P/E
N/A
P/B
0.71
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 29% YoY and by 22% from the previous quarter
The stock's price to book (P/B) is 75% less than its 5-year quarterly average of 2.8 and 29% less than its last 4 quarters average of 1.0
The company's equity has shrunk by 57% YoY and by 17% QoQ
Efficiency
How efficient is Matinas BioPharma Holdings business performance
Matinas BioPharma Holdings's ROIC has plunged by 82% YoY and by 9% from the previous quarter
The ROE has dropped by 50% year-on-year but it is up by 3.1% since the previous quarter
The return on assets has declined by 35% year-on-year but it is up by 8% since the previous quarter
Dividends
What is MTNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MTNB.
Financial health
How did Matinas BioPharma Holdings financials performed over time
Matinas BioPharma Holdings's total assets is 109% higher than its total liabilities
Matinas BioPharma Holdings's total assets has decreased by 39% YoY and by 4.8% QoQ
MTNB's current ratio is down by 35% year-on-year but it is up by 11% since the previous quarter
Matinas BioPharma Holdings's debt is 57% lower than its equity
The company's debt to equity has surged by 87% YoY and by 13% QoQ
The company's equity has shrunk by 57% YoY and by 17% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.